Cardiorenal and Humoral Properties of a Novel Direct Soluble Guanylate Cyclase
نویسندگان
چکیده
Guido Boerrigter, Lisa C. Costello-Boerrigter, Alessandro Cataliotti, Toshihiro Tsuruda, Gail J. Stimulator BAY 41-2272 in Experimental Congestive Heart Failure Cardiorenal and Humoral Properties of a Novel Direct Soluble Guanylate Cyclase Print ISSN: 0009-7322. Online ISSN: 1524-4539 Copyright © 2003 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Circulation doi: 10.1161/01.CIR.0000055737.15443.F8 2003;107:686-689; originally published online January 27, 2003; Circulation. http://circ.ahajournals.org/content/107/5/686 World Wide Web at: The online version of this article, along with updated information and services, is located on the
منابع مشابه
Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure.
BACKGROUND BAY 41-2272 is a recently introduced novel orally available agent that directly stimulates soluble guanylate cyclase (sGC) and sensitizes it to its physiological stimulator, nitric oxide. To date, its therapeutic actions in congestive heart failure (CHF) remain undefined. We characterized the cardiorenal actions of intravenous BAY 41-2272 in a canine model of CHF and compared it to n...
متن کاملTargeting heme-oxidized soluble guanylate cyclase in experimental heart failure.
Soluble guanylate cyclase is a heterodimeric enzyme with a prosthetic heme group that, on binding of its main ligand, NO, generates the second messenger cGMP. Unlike conventional nitrovasodilators, the novel direct NO- and heme-independent soluble guanylate cyclase activator BAY 58-2667 is devoid of non-cGMP actions, lacks tolerance development, and preferentially activates NO-insensitive heme-...
متن کاملActivation of heme-free soluble guanylate cyclase with cinaciguat has beneficial cardiorenal actions when added to furosemide in experimental heart failure
Background Volume overload and sodium retention in congestive heart failure (HF) are usually treated with loop diuretics. However, worsening renal function is frequently observed and is associated with worse outcomes. Soluble guanylyl cyclase (sGC) plays an important role in renal function. Importantly, sGC activation can be impaired in cardiorenal disease states, which can be due to not only d...
متن کاملM‐Atrial Natriuretic Peptide and Nitroglycerin in a Canine Model of Experimental Acute Hypertensive Heart Failure: Differential Actions of 2 cGMP Activating Therapeutics
BACKGROUND Systemic hypertension is a common characteristic in acute heart failure (HF). This increasingly recognized phenotype is commonly associated with renal dysfunction and there is an unmet need for renal enhancing therapies. In a canine model of HF and acute vasoconstrictive hypertension we characterized and compared the cardiorenal actions of M-atrial natriuretic peptide (M-ANP), a nove...
متن کاملRiociguat prevents fibrotic tissue remodelling and improves survival in salt-sensitive Dahl rats
Background A direct pharmacological stimulation of soluble guanylate cyclase (sGC) is an emerging therapeutic approach to the management of various cardiopulmonary disorders associated with endothelial dysfunction. Novel sGC stimulators, including riociguat (BAY 63-2521), have a dual mode of action: they sensitize sGC to endogenously produced nitric oxide (NO) and also directly stimulate sGC in...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2003